We aimed to assess the prevalence and management of clinical familial hypercholesterolaemia (FH) among patients with acute coronary syndrome (ACS).
Introduction
Heterozygous familial hypercholesterolaemia (FH) is an autosomaldominant genetic disorder with an estimated prevalence of 1/200 -1/500 in the general population. 1, 2 Early identification of patients with FH is important, because appropriate treatment may reduce the risk of premature atherosclerosis. 3, 4 Mainly two diagnosis algorithms are used to diagnose FH in the general population. The Dutch Lipid Clinic Network algorithm is a scoring system based on clinical factors endorsed by many guidelines worldwide, such as the European Society of Cardiology, the National Lipid Association in the USA, the International FH Foundation, and the European Atherosclerosis Society. 1,5 -7 The Simon Broome Register criteria from NICE guidelines in the UK requires both an elevated LDL-cholesterol .4.9 mmol/L (or total cholesterol .7.5 mmol/L) along with history of premature atherosclerosis. 8, 9 Underdiagnosis of FH in the general population has recently been recognized as an important issue, and for many patients with FH who are unaware of their disease, the first clinical manifestation is an acute coronary syndrome (ACS). 10 Identifying FH during hospitalization for ACS would allow specific counselling for diet and cardiovascular risk factors, ensure high-dose statin prescription at discharge as well as appropriate referral to lipid clinics for identification of family members. 11 -13 In addition, new lipid-lowering drugs inhibiting proprotein convertase subtilisin/kexin 9 (PCSK9) might be particularly promising in addition to maximal statin dose among patients with FH. 14 However, the proportion of patients hospitalized with ACS who have FH remains uncertain, with prevalence ranging from 12% to .50% in patients ,60 years old according to two small previous studies. 15, 16 To fill these gaps, we aimed to assess the prevalence of FH and its 1-year management in a large multi-centre cohort of patients with ACS.
Methods

Study population
This study was performed within the framework of the SPUM-ACS (Special Program University Medicine-Acute Coronary Syndromes) cohort study designed to evaluate the determinants and consequences of ACS in the general population. Details regarding the methods of the SPUM-ACS study were previously reported, 17 -19 and are provided in Supplementary material online. Of the 5713 patients in the SPUM-ACS study hospitalized between 2009 and 2014, we excluded 935 patients with missing values for total cholesterol, HDL-cholesterol, and triglycerides (Supplementary material online, Figure S1 ). Thus, the final sample for this analysis was 4778.
Ethics statement
The study protocol was approved by the institutional review board of all participating centres and all patients provided written, informed consent.
Diagnosis of familial hypercholesterolaemia
We assessed the presence of FH based on age, personal and family history of premature atherosclerosis, and LDL-cholesterol levels. We used the validated Dutch Lipid Clinic Network algorithm recommended by many guidelines to diagnose FH in the general population in central European countries. 1,5 -7 Clinical signs of lipid accumulation in the tissue, as well as family history of elevated LDL-cholesterol were not available in our study sample and missing information was counted as zero in the Dutch Lipid Clinic algorithm. A possible diagnosis was considered when the Dutch Lipid Clinic Network score was 3 -5, and a probable/definite FH when the score was 6 or higher. 20 We also used the Simon Broome Register criteria from NICE guidelines in the UK. The diagnosis of possible FH requires both an elevated LDL-cholesterol .4.9 mmol/L (or total cholesterol .7.5 mmol/L) along with family or personal history of premature atherosclerosis. 8, 9 Stratified analysis in 3353 patients not using lipid-lowering drugs before hospitalization yielded about similar prevalence of 1.3% (95% CI 1.0 -1.8%) for probable/definite FH, and 19.4% (95% CI 18.0-20.7%) for possible FH according to the Dutch Lipid Clinic algorithm (Supplementary material online, Figure S3A ). Among 1425 patients using lipid-lowering drugs before hospitalization, the prevalence of probable/definite FH reached 2.4% (95% CI 1.7 -3.3%) (Supplementary material online, Figure S3B ). Sensitivity analysis in 3493 patients with blood draw within 72 h after symptoms onset, or in 4165 patients without acute renal failure or dialysis, or in 3677 patients without severe hyperglycaemia at admission, or in 4186 patients without alcohol excessive use yielded similar results for prevalence of FH (Supplementary material online, Figure S4 ).
Baseline characteristics of the 4778 participants with respect to FH diagnosis are presented in Table 1 . Compared with patients without FH, patients with FH were younger, had higher proportion of personal or family history of premature coronary heart disease (CHD), were more frequently smokers, but were less frequently suffering from hypertension, diabetes, or pre-existing cardiovascular disease. Baseline characteristics with respect to the use of lipid-lowering drugs before hospitalization are presented in Supplementary material online, Table S3 . Compared with patients not using lipid-lowering drugs before hospitalization, those with lipid-lowering drugs were older, had more frequently pre-existing cardiovascular disease or diabetes, but were less frequently current smokers.
Quality of care during and 1-year after hospitalization for ACS in 977 patients with possible FH according to either Dutch or Simon Broome algorithm is shown in Tables 2 and 3. Among 78 patients with probable/definite FH according to the Dutch Lipid Clinic algorithm, 61.8% had an ST-segment elevation myocardial infarction, and 69.7% were prescribed high-dose statins at discharge ( Table 2 and Figure 2) . After 1 year, 879 patients with possible FH were alive and had available follow-up visit information, including a subsample of 508 patients with measured LDL-cholesterol levels. Among the 69 patients with probable/definite FH according to the Dutch Lipid Clinic algorithm, 44 (64.7%) had high-dose statins ( Table 3 and Figure 2 ). In the subsample of 43 patients with probable/ definite FH and 1-year LDL-cholesterol available, 29 (69.0%) had decreased their LDL-cholesterol of at least 50% over the year, and 2 (4.6%) had an LDL-cholesterol levels of 1.8 mmol/L or below ( Table 3) .
Discussion
In this large cohort study of patients with ACS, the prevalence of probable/definite FH reached 1.6 and 4.8% when considering only younger adults with premature ACS. These estimates are three to six times higher than those of the general population using similar diagnosis algorithms. 2 More than a fourth of patients with probable/definite FH were not discharged or were not using high-dose statins 1-year after their hospitalization, or could not reach 50% reduction of their LDL-cholesterol as recommended after ACS. The prevalence of FH has never been studied in large cohorts of patients with ACS. Previous studies had very small sample size, included patients 20 years ago, and used heterogeneous definition for FH, considering either genetic mutation rates or clinical criteria. 15 and 3% had monogenic alteration found in FH. 22 More recently, a 2% rate of rare genetic alteration in LDL-cholesterol receptor was reported in young patients with premature myocardial infarction. 23 In our study of .4700 patients with ACS, we found a high prevalence of 1.6% for probable/definite FH. As expected, prevalence of probable/definite FH was higher in patients using statins before hospitalization (2.4%), than those not taking statins (1.3%). These estimates are higher than the prevalence of probable/definite FH thought to be 0.2% (1/500) in the general population. 1 In a large remains a challenge. 25 We found that among patients with possible FH that were not using statins but aspirin before hospitalization for ACS, 86% of them used statins 1-year after discharge, confirming that in most cases, undertreatment of FH is due to underdiagnosis rather than statins intolerance. During hospitalization for ACS, screening for FH can be performed at low cost, by assessing familial history of premature CHD and LDL-cholesterol levels. At hospital discharge and after 1-year, we reported that more than a fourth of patients with probable/definite FH and ACS were not using optimal statin doses, and that nearly all could not reach 1.8 mmol/L for LDL-cholesterol 1-year after their ACS. As future perspectives, new lipid-lowering drugs targeting PCSK9 have shown large reduction of LDL-cholesterol levels compared with placebo in FH patients with maximal tolerated statin doses, and phase III placebocontrolled clinical trials examining long-term clinical outcomes are ongoing. 14 If efficacy for cardiovascular prevention is confirmed, many patients with both ACS and FH might benefit from PCSK9 inhibitors, providing they are identified during the hospitalization. Our study has several limitations. First, we did not perform genetic molecular analysis to identify monogenic mutations associated with FH. The detection rate for monogenic disorder is 25% among patients with a diagnosis of possible FH, and 75% in patients with probable/definite FH. 26, 27 Thus, our estimates should not be compared with prevalence studies of genetically confirmed FH. However, the aim of our study was to estimate the prevalence of clinical FH, because in patients with ACS and a phenotype diagnosis of FH, high-dose statins will be indicated, as recommended by guidelines. 1, 5, 7 In the setting of ACS, genetic tests might be used for screening family members. 7 Second, we were not able to assess all clinical criteria of diagnosis algorithms, such as Achilles xanthoma or LDL-cholesterol in family members. This is a limitation of previous studies about FH prevalence 2, 15, 16 and this would likely underestimate the true prevalence of FH. However, when measurement of LDL-cholesterol is systematically performed, such as in patients with ACS, the importance of clinical signs of lipid accumulation in the tissue to help identify patients with FH might be limited. In addition, when family history of premature CHD is known, the importance missing information about LDL-cholesterol levels in family members may be limited, as 85% of families with premature CHD have lipid abnormalities at the 95% percentile. 22 Third, clinical diagnosis algorithms for diagnosis of FH have never been validated in patients with ACS. However, accuracy of self-reported information Prevalence and management of familial hypercholesterolaemia regarding family history was similar in patients with and without preexisting cardiovascular disease. 28 Finally, cholesterol levels have been shown to decrease 24 h after admission for ACS. However, blood samples were measured from the first blood draw in the emergency department or at coronary angiography, and our sensitivity analysis performed only in patients with a short time interval between symptom onset and blood draw yielded similar results.
Conclusions
The high prevalence of FH in patients presenting with ACS may advocate for better identification of the disorder during the hospital stay, in order to organize specific referral to lipid clinics or primary care physicians for diet counselling, long-term maintenance of highdose statins, and identification of family members. In addition, new lipid-lowering drugs targeting PCSK9 might represent a promising therapeutic option in addition to statins for many patients with ACS and FH.
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